Results 71 to 80 of about 4,026 (142)

ESTIMATION OF ENTECAVIR IN PURE AND PHARMACEUTICAL FORMULATION BY USING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

, 2018
A rapid and precise Reverse Phase High Performance Liquid Chromatographic method has been developed for the validated of Entecavir, in its pure form as well as in tablet dosage form. Chromatography was carried out on a Phenomenex Gemini C18 (4.6 x 250mm,
Rameshpetchi Rajendran, Devikasubramaniyan*, Ramya Sri Sura, M. Praveen Kumar, L.Soundharya, M. Arun Kumar, M. Sumalatha
core   +1 more source

Diagnostic Challenge of Contralateral Intranodal Thyroid Inclusions in a Patient With Synchronous Oropharyngeal and Papillary Thyroid Carcinoma: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Distinguishing benign intranodal thyroid inclusions from metastatic papillary thyroid carcinoma is vital in synchronous malignancies to prevent overstaging. Integrating morphological analysis with BRAF VE1 immunohistochemistry ensures diagnostic precision to align management with the true pathological stage, avoiding unnecessary aggressive ...
Bo‐Cheng Rau, Yun‐An Chen, Chun‐Wei Huang   +2 more
wiley   +1 more source

Entecavir monotherapy for lamivudine-refractory chronic hepatitis B

, 2008
Evaluation of: Sherman M, Yurdaidin C, Simsek H et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical and serology outcomes through 96 weeks. Hepatology 48, 99-108 (2008).
Dalekos, G. N., Goulis, I.
core   +1 more source

Comparison of the Efficacy of Tenofovir and Entecavir for the Treatment of Nucleos(T) Ide‑Naive Patients with Chronic Hepatitis B [PDF]

, 2015
Background: An important goal in the treatment of chronic hepatitis B virus (HBV) infection is to prevent hepatocellular carcinoma and liver cirrhosis by suppressing HBV replication.
Park, MJ, Kwon, YJ, Shim, SG, Lee, HS
core   +1 more source

Effect and safety analysis of Yiqi Yangxue Jiedu decoction combined with entecavir in the treatment of male patients with decompensated hepatitis B cirrhosis [PDF]

Journal of Men's Health
Background: This study aimed to evaluate the efficacy and safety of Yiqi Yangxue Jiedu Decoction & Entecavir in male patients with decompensated hepatitis B cirrhosis.
Mingli Jia
doaj   +1 more source

Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection [PDF]

, 2017
Young-Mo Yang, Eun Joo Choi Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, South Korea Background: Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are recommended as the first-line therapy for chronic hepatitis B (CHB)
Choi EJ, Young-Mo Yang, Eun Joo Choi, Yang YM   +3 more
core   +1 more source

qHBsAg outperforms ALT/qHBsAg ratio in predicting HBsAg seroclearance after cessation of entecavir versus tenofovir

Biomedical Journal
Background: We aimed to establish the optimal value of the alanine aminotransferase (ALT)/quantitative HBsAg (qHBsAg) ratio and qHBsAg level at end of treatment (EOT) to predict HBsAg seroclearance following cessation of entecavir versus tenofovir ...
Hsing-Yun Lee, Cheng-Yuan Peng, Kwong-Ming Kee, Tsung-Hui Hu, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu, Chien-Hung Chen   +7 more
doaj   +1 more source

Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients

The Saudi Journal of Gastroenterology, 2015
Background/Aims: This study aimed to evaluate the antiviral response and safety of tenofovir (TDF) versus entecavir (ETV) in treatment-naïve CHB patients. Patients and Methods: We performed a retrospective cohort study of treatment-naive CHB patients who
Hyung Min Yu, So Young Kwon, Jiwan Kim, Hyun Ah Chung, Se Woong Kwon, Taek Gun Jeong, Sang Hee An, Gyung Won Jeong, Seon Ung Yun, Jae Ki Min, Jeong Han Kim, Won Hyeok Choe   +11 more
doaj   +1 more source

Impact of tenofovir vs. entecavir treatment on progression of chronic hepatitis B: A nationwide cohort study

JHEP Reports
Background & Aims: Conflicting evidence exists on hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B (CHB) receiving tenofovir vs. entecavir.
Wan-Jung Wu, Wen-Jie Liu, Chih-Lin Lin, Chun-Jen Liu, Yi-Wen Huang, Jui-Ting Hu, Ming-Whei Yu   +6 more
doaj   +1 more source

Entecavir [PDF]

Reactions Weekly, 2020
openaire   +2 more sources